FLT3 and acute myeloid leukemia: Mice receiving 32D-FLT3ITD AML cells and an untreated graft showed no increased human CD135+ counts in the BM (1.1 ± 1.6%, n = 5), spleen (0.3 ± 0.1%, n = 5), or liver preparations (1.2 ± 1.3%, n = 5) (Figures 4A,B and Table S3).